AACC 2019 | Plasma Calprotectin Immunoassay | PETIA
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
post-template-default,single,single-post,postid-19293,single-format-standard,bridge-core-1.0.6,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.2,qode-theme-bridge,wpb-js-composer js-comp-ver-6.0.5,vc_responsive

Plasma Calprotectin at AACC 2019

AACC 2019, Anaheim Plasma Calprotectin

Plasma Calprotectin at AACC 2019

learn more about Plasma Calprotectin* at AACC 2019

Calprotectin* is a promising biomarker for the diagnosis of bacterial infections and sepsis

*Gentian Plasma Calprotectin: CE-marked – US: for research only

LEARN MORE ABOUT Plasma Calptorectin AT AACC
CE-marked – US: for research only

Particle-Enhanced Turbidimetric Immunoassay (PETIA)

The Gentian Calprotectin Immunoassay (GCAL®) is the first Particle-Enhanced Turbidimetric Immunoassay (PETIA) for quantitative analysis of total calprotectin in plasma. The assay is rapidly performed in only 10 minutes. It can be applied on a wide range of automated clinical chemistry analysers.

Short turnaround time: sample to reportable result

The assay allows for rapid and flexible random-access use and is an ideal solution for high throughput applications in the routine laboratory. Can be applied on all automated platforms, giving short turnaround time from sample to reportable result.

Areas of use for plasma calprotectin

In combination with CRP to identify sepsis vs postoperative inflammation (1)

Early biomarker of bacterial infections (2)

Discriminate bacterial sepsis from viral infections (3)

Diagnosis of rheumatoid arthritis (4)

Diagnosis of appendicitis (5)

Diagnosis of sclerosis (6)

Calprotectin acknowledged as a promising biomarker by the industry at EuroMedLab2019

Gentian hosted the Educational Workshop “Plasma Calprotectin: a promising early biomarker for diagnosis of bacterial infections and sepsis” at EuroMedlab 2019 in Barcelona in May.

The talks discussed calprotectin and other biomarkers’ role in diagnosis of severe infections and sepsis. The presentations showed studies and results supporting the ability of calprotectin to discriminate patients with acute infections from patients with other states of inflammatory responses, including patients with heart failure, chronic obstructive pulmonary disease and asthma presented in the emergency department setting. Highlights include:

Calprotectin is an independent predictor of 28-day mortality in septic patients and promising biomarker in early diagnosis, risk stratification, and evaluation of prognosis in septic patients (7)

Calprotectin is an accurate marker of sepsis in very low birth weight newborns (8)

Calprotectin has significant diagnostic accuracy for the bacterial etiology of sepsis (3)


1. Simm, M., et al (2016). Biomark Med 10, 811-818

2. Jonsson, N., et al. (2017). Crit Care Resusc 19, 205- 213

3. Bartáková, E. et al (2019). Diagn Microbiol Infect Dis 93, 219-226

4. Nordal, H. H., et al (2017) Arthritis Res Ther 19:3 doi: 10.1186/s13075-016-1201-0

5. Cikot, M., et al (2016) World J Emerg Surg 11:17 doi: 10.1186/s13017- 016-0062-9

6. van Bon, L., et al (2014) Ann Rheum Dis 73:1585-1589

7. Gao, S. et al (2015) Am J Emerg Med 33 1278–1282

8. Terrin et al (2011), Clin Dev Immunol.: 2011:291085